Zambon Pharma has received approval from Chinese regulatory authorities and launched Fluimucil (N-acetylcysteine).

Zambon, a multinational chemical-pharmaceutical company founded on the history and values of an Italian family and committed to innovate cure and care to make patients’ lives better, announces the ...

Fluimucil IV is now available to patients across China as an essential hospital-based treatment for respiratory conditions. Credit: Explode/Shutterstock.

The intravenous formulation of Fluimucil® will initially be distributed in a selection of Chinese hospitals and represents another step forward in Zambon's expansion strategy in the Chinese market.

" The approval of Fluimucil® IV in China is a major recognition of the scientific rigor with which we conducted the clinical trials and the quality of our collaboration with local research ...

MILAN, June 24, 2025--Zambon, a multinational chemical-pharmaceutical company founded on the history and values of an Italian family and committed to innovate cure and care to make patients’ lives ...

Zambon chief medical officer and research and development head Paola Castellani stated: “The approval of Fluimucil IV in China is a major recognition of the scientific rigour with which we conducted ...